Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

NCT03498521 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03498521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03498521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 10, 2018
Completion date
November 7, 2024
Enrollment
529 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of unknown primary site